Asheena Keith1, Yuelei Dong, Jonathan Shuter, Seth Himelhoch. 1. *Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD; and †Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center and the Albert Einstein College of Medicine, New York, NY.
Abstract
CONTEXT: Smoking is responsible for increased morbidity and mortality in HIV-infected smokers. OBJECTIVE: To assess the efficacy of behavioral interventions for smoking cessation among HIV-infected smokers compared with the standard care. DATA SOURCES: PubMed, Cochrane, CINHAL, PsychINFO, and Google Scholar were searched for randomized controlled trials published in English. STUDY SELECTION: Eligibility criteria were randomized controlled trials with targeted behavioral interventions compared with standard of care (or enhanced standard of care) aimed at promoting abstinence in HIV-infected smokers. A total of 17,384 articles were found and 17,371 were excluded; 13 full text articles were obtained and reviewed, and 8 met the eligibility criteria (Κ = 0.94). DATA EXTRACTION: The primary outcome was expired carbon monoxide-verified 7-day point prevalence abstinence rates. Adequate sequence generation and freedom from incomplete or selective outcome reporting was used to assess study quality. RESULTS: A total of 1822 subjects from 8 studies yielded a statistically significant effect of behavioral interventions in increasing abstinence in HIV-infected smokers with a moderate effect size (relative risk: 1.51; 95% confidence interval: 1.17 to 1.95). Those studies with interventions of 8 sessions or more had a large effect size for abstinence (relative risk: 2.88; 95% confidence interval: 1.89 to 4.61). When stratified by the number of sessions, there was no heterogeneity. CONCLUSIONS: Targeted behavioral smoking cessation interventions are efficacious. Interventions consisting of 8 sessions or more had the greatest treatment efficacy.
CONTEXT: Smoking is responsible for increased morbidity and mortality in HIV-infected smokers. OBJECTIVE: To assess the efficacy of behavioral interventions for smoking cessation among HIV-infected smokers compared with the standard care. DATA SOURCES: PubMed, Cochrane, CINHAL, PsychINFO, and Google Scholar were searched for randomized controlled trials published in English. STUDY SELECTION: Eligibility criteria were randomized controlled trials with targeted behavioral interventions compared with standard of care (or enhanced standard of care) aimed at promoting abstinence in HIV-infected smokers. A total of 17,384 articles were found and 17,371 were excluded; 13 full text articles were obtained and reviewed, and 8 met the eligibility criteria (Κ = 0.94). DATA EXTRACTION: The primary outcome was expired carbon monoxide-verified 7-day point prevalence abstinence rates. Adequate sequence generation and freedom from incomplete or selective outcome reporting was used to assess study quality. RESULTS: A total of 1822 subjects from 8 studies yielded a statistically significant effect of behavioral interventions in increasing abstinence in HIV-infected smokers with a moderate effect size (relative risk: 1.51; 95% confidence interval: 1.17 to 1.95). Those studies with interventions of 8 sessions or more had a large effect size for abstinence (relative risk: 2.88; 95% confidence interval: 1.89 to 4.61). When stratified by the number of sessions, there was no heterogeneity. CONCLUSIONS: Targeted behavioral smoking cessation interventions are efficacious. Interventions consisting of 8 sessions or more had the greatest treatment efficacy.
Authors: D R Bailey Miles; Usama Bilal; Heidi E Hutton; Bryan Lau; Catherine R Lesko; Anthony Fojo; Mary E McCaul; Jeanne Keruly; Richard D Moore; Geetanjali Chander Journal: J Health Care Poor Underserved Date: 2019
Authors: Krysten W Bold; Yanhong Deng; James Dziura; Elizabeth Porter; Keith M Sigel; Jessica E Yager; David M Ledgerwood; Steven L Bernstein; E Jennifer Edelman Journal: Transl Behav Med Date: 2022-07-07 Impact factor: 3.626
Authors: Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare Journal: J Neuroimmune Pharmacol Date: 2019-12-13 Impact factor: 4.147
Authors: Eric A Engels; Elizabeth L Yanik; Willian Wheeler; M John Gill; Meredith S Shiels; Robert Dubrow; Keri N Althoff; Michael J Silverberg; John T Brooks; Mari M Kitahata; James J Goedert; Surbhi Grover; Angel M Mayor; Richard D Moore; Lesley S Park; Anita Rachlis; Keith Sigel; Timothy R Sterling; Jennifer E Thorne; Ruth M Pfeiffer Journal: Clin Infect Dis Date: 2017-08-15 Impact factor: 9.079